GH Secretagogues: Peptide Class Overview

Growth hormone secretagogues (GHS) are peptides that stimulate endogenous GH release from the anterior pituitary. Unlike recombinant human GH, which bypasses the pituitary entirely, GH secretagogues act upstream, preserving the hypothalamic-pituitary feedback axis. The class encompasses two pharmacologically distinct subfamilies: GHRH analogs that act on the GHRH receptor (GHRHR), and GH-releasing peptides (GHRPs) that act on the ghrelin receptor (GHSR-1a). Several compounds in clinical or research use combine features of both families.

This page is a high-level orientation to the class. Detailed mechanistic, pharmacokinetic, and evidence profiles are available on each compound’s hub page.

All GH secretagogues share a single clinical target: amplifying the pulsatile GH signal from the anterior pituitary. The downstream consequences of elevated GH include hepatic IGF-1 production, lipolysis, lean-mass accretion, and a variety of pleiotropic effects on bone, sleep architecture, and tissue repair.

The class is unified by its indirect mechanism. Because secretagogues work through pituitary receptors rather than substituting for GH directly, somatostatin-mediated negative feedback remains intact. This pharmacological feature is central to arguments that secretagogues carry a lower risk of supraphysiological GH excursion than exogenous GH replacement, though formal long-term comparative data are limited.

The two receptor families the class uses are:

GHRHR (GHRH receptor): A Gs-coupled GPCR on pituitary somatotrophs. Activation raises cAMP, activates PKA, phosphorylates CREB, and drives GH1 gene transcription (PMID: 9409319).
GHSR-1a (ghrelin receptor): A constitutively active Gq/11-coupled GPCR. Stimulation mobilizes intracellular Ca2+ and potentiates GH release via a mechanism synergistic with, but distinct from, GHRHR signaling (PMID: 9430547).

The synergy between the two pathways is exploited clinically. Co-administration of a GHRH analog and a GHRP produces GH pulses substantially larger than either agent alone, a phenomenon confirmed in controlled studies (PMID: 8627573).

Brief History of the Class

1982. Vale, Rivier, and colleagues at the Salk Institute sequenced human GHRH from a pancreatic tumor. They found that the first 29 amino acids (GHRH 1-29) retained full receptor-binding and GH-releasing activity, establishing the minimum pharmacophore (PMID: 6812220).

1984-1990. The first synthetic GHRH fragment, later named sermorelin (GHRH 1-29 NH2), entered clinical development. Pediatric GH-deficiency trials established efficacy.

1982-1997. Cytoprotective and GH-releasing pentapeptide sequences were developed at Tulane and Merck, leading to the GHRP subfamily (GHRP-6, GHRP-2). Hexarelin emerged from Italian and French groups as a potent, cyclized hexapeptide GHRP (PMID: 9386083).

1997. The FDA approved sermorelin (Geref, Serono) for both diagnostic testing of pituitary GH reserve and treatment of pediatric GH deficiency (FDA NDA 020458).

1999. The endogenous GHSR-1a ligand was identified as ghrelin, a 28-amino-acid acylated peptide produced in the gastric fundus. This discovery provided the molecular rationale for the GHRP pharmacology that had been demonstrated empirically for over a decade (PMID: 9430547).

2004-2010. Modified GHRH analogs with prolonged half-lives reached development. CJC-1295 (with and without drug affinity complex, DAC) extended GHRHR activation from minutes to days. Tesamorelin, a GHRH analog with a trans-3-hexenoic acid N-terminal modification, entered Phase III trials for HIV-associated lipodystrophy.

2010. The FDA approved tesamorelin (Egrifta, Theratechnologies) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (FDA NDA 022505). This remains the only FDA approval in the class granted to a GHRH analog for a metabolic endpoint.

2014. A Phase III trial confirmed tesamorelin’s efficacy for visceral adiposity in HIV-positive patients; secondary analyses noted favorable effects on triglycerides and cognitive function (NCT01263899).

2010-present. Ipamorelin, a selective pentapeptide GHRP with minimal off-target effects on cortisol and prolactin, became widely used in combination protocols. Research interest has grown in dual-action compounds and oral secretagogues (e.g., MK-677/ibutamoren), though those are outside the scope of this page.

Shared Pathway: Receptor Pharmacology

The diagram below maps the two receptor families and their convergence on GH release.

flowchart TD
    GHRH["GHRH analog\n(Sermorelin, Tesamorelin,\nCJC-1295)"] --> GHRHR["GHRH Receptor\n(Gs-coupled GPCR)\non pituitary somatotroph"]
    GHRP["GHRP\n(Ipamorelin, Hexarelin)"] --> GHSR["Ghrelin Receptor\nGHSR-1a\n(Gq/11-coupled GPCR)"]

    GHRHR --> cAMP["↑ cAMP\nPKA activation\nCREB phosphorylation"]
    GHSR --> Ca2["↑ intracellular Ca2+\nPKC activation"]

    cAMP --> GH["GH gene transcription\n& vesicle exocytosis"]
    Ca2 --> GH

    GH --> Pulse["Pulsatile GH secretion\n(portal circulation)"]

    Pulse --> IGF1["Hepatic IGF-1 synthesis\n(main anabolic mediator)"]
    Pulse --> Direct["Direct GH effects:\nlipolysis, glucose metabolism,\ntissue repair"]

    IGF1 --> Feedback["Negative feedback:\nSomatostatin release\nfrom hypothalamus"]
    Feedback --> GHRHR
    Feedback --> GH

Compound Comparison Table

Compound	Receptor	Half-life (approx.)	FDA Status	Primary Research Context
Sermorelin	GHRHR	10-20 min (IV)	Formerly approved (NDA 020458); compounding use	Pituitary GH reserve; pediatric GHD; adult GH optimization
Tesamorelin	GHRHR	~26 min	Approved (NDA 022505) for HIV lipodystrophy	Visceral fat reduction; metabolic endpoints; cognitive function
CJC-1295	GHRHR	~30 min (no DAC); ~6-8 days (with DAC)	No FDA approval; research compound	Extended GHRH signaling; combination protocols
Ipamorelin	GHSR-1a	~2 h	No FDA approval; research compound	Selective GH pulse; combination with GHRH analogs; sleep
Hexarelin	GHSR-1a + CD36	~1-2 h	No FDA approval; research compound	Potent GH release; cardiac protection via CD36; combination

Notes on half-life: Values reflect plasma elimination half-life from pharmacokinetic studies. Biological duration of GH elevation exceeds plasma half-life for most of these agents.

Key Differentiators Within the Class

Sermorelin vs. tesamorelin. Both are GHRH analogs, but tesamorelin carries a trans-3-hexenoic acid modification at the N-terminus that improves stability and prolongs receptor engagement. Tesamorelin’s FDA approval rests on Phase III data showing significant visceral fat reduction in HIV-positive adults (PMID: 20581397). Sermorelin’s clinical record is larger and older but lacks a current FDA-approved indication.

CJC-1295 with vs. without DAC. The drug-affinity complex (DAC) variant covalently binds to circulating albumin, extending the plasma half-life from ~30 minutes to approximately 6-8 days. This shifts the pharmacological profile from pulsatile to tonic GHRH stimulation. Whether tonic vs. pulsatile GHRHR activation produces equivalent downstream outcomes is an open research question.

Ipamorelin’s selectivity. Among GHRPs, ipamorelin is distinguished by minimal stimulation of cortisol, prolactin, or ACTH at therapeutic concentrations. Hexarelin, by contrast, produces more robust GH release but also stimulates cortisol and prolactin more substantially, which is relevant in long-term use contexts (PMID: 9386083). Hexarelin also binds CD36, a scavenger receptor on cardiac tissue, a property under investigation for cardioprotective effects independent of GH (PMID: 10523417).

Combination pharmacology. Because GHRHR and GHSR-1a signal through distinct intracellular cascades, co-stimulation is synergistic. Multiple studies have quantified this: combined GHRH + GHRP produces GH AUC responses several-fold greater than either ligand alone (PMID: 8627573). This forms the pharmacological basis for widely used clinical combinations such as sermorelin + ipamorelin and CJC-1295 + ipamorelin.

Research Outlook and Open Questions

Sustained vs. pulsatile stimulation. The physiological GH axis is defined by discrete pulses, primarily nocturnal. Long-acting GHRH analogs (CJC-1295 with DAC) produce a more continuous GHRHR stimulus. Whether this preserves, attenuates, or abolishes pulsatile GH secretion over extended use, and what the downstream metabolic consequences are, has not been resolved in adequately powered long-term trials.

Cognitive and neuroprotective endpoints. Tesamorelin’s Phase III cognitive substudy (NCT01263899) and a subsequent trial in mild cognitive impairment (NCT01561196) generated hypotheses about GH/IGF-1 axis effects on brain structure and function. Replication in non-HIV populations with longer follow-up has not occurred.

Cardiac effects of hexarelin. Hexarelin’s CD36 binding raises the possibility of direct cardiac effects unrelated to GH. Preclinical data are intriguing (PMID: 10523417), but no human cardiac-endpoint trials have been completed.

Receptor desensitization. Chronic GHSR-1a stimulation with GHRPs leads to receptor downregulation in animal models. The clinical significance, optimal dosing interval, and reversibility in humans are not established from controlled data.

Regulatory trajectory. All compounds in this class other than tesamorelin lack current FDA-approved indications. Research use and compounding occur in a regulatory context that has shifted; the FDA’s 2023 guidance on compounded peptides is relevant to clinical availability, though it remains subject to ongoing policy evolution.

Compound Hubs

Detailed evidence, mechanism, pharmacokinetics, safety, and dose-response data are organized by compound:

This page is for research and educational purposes. It does not constitute medical advice, dosing guidance, or a recommendation to use any compound. Consult a licensed clinician for individualized guidance.